^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
04/28/2020
Excerpt:
Sprycel is indicated for the treatment of adult patients with:...Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
Secondary therapy:
Chemotherapy
Source:
Published date:
04/28/2020
Excerpt:
Sprycel is indicated for the treatment of paediatric patients with:...newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.
Source:
Published date:
12/21/2018
Excerpt:
SPRYCEL is a kinase inhibitor indicated for the treatment of...pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in
combination with chemotherapy
Secondary therapy:
Chemotherapy
Source:
Published date:
12/21/2018
Excerpt:
SPRYCEL is a kinase inhibitor indicated for the treatment of...adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy
Source:
Excerpt:
INDUCTION REGIMENS FOR Ph-POSITIVE ALL: Other Recommended regimens…TKI + vincristine + dexamethasone…TKI options include (in alphabetical order): bosutinib, dasatinib, imanitib, nilotinib or ponatinib.
Secondary therapy:
vincristine + dexamethasone
Source:
Title:
A randomized trial to compare with or without realgar-Indigo naturalis formula during dasatinib and conventianl chemotherapy treating children's Ph+ acute lymphoblastic leukemia
Excerpt:
...BCR-ABL1 fusion gene was found by molecular genetics (FISH/NGS/PCR) or ph+ chromosome / t (9,22) in cytogenetic....
Trial ID:
Source:
Title:
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial
Published date:
07/06/2023
Excerpt:
Dasatinib plus EsPhALL chemotherapy is safe and active in paediatric Ph-positive acute lymphoblastic leukaemia. 3-year event-free survival was similar to that of previous Ph-positive acute lymphoblastic leukaemia trials despite the limited use of HSCT in first complete remission.
Secondary therapy:
Chemotherapy
DOI:
10.1016/S2352-3026(23)00088-1
Trial ID:
Source:
Title:
FINAL ANALYSIS OF THE GMALL-PH-01 TRIAL: PHASE II STUDY OF STANDARD CHEMOTHERAPY IN COMBINATION WITH DASATINIB IN FIRST LINE TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Published date:
05/14/2020
Excerpt:
19 pts were included in 12 centres. Median age was 45 (31-53) years, male/female 12/7, with 2 pre B-ALL and 17 common ALL pts and 10 of 19 pts expressed the p210BCR-ABL1 transcript...At the EOS timepoint (median time from start of study 118 [104-136] d), 12 pts were alive and in CR, one additional CR pt had discontinued due to renal toxicity…Allogeneic SCT was performed in all but two CR patients with encouraging overall survival of 68% at 2 years. Despite the antileukemic efficacy of this intensive approach, current GMALL regimens for Ph+ ALL aim to reduce induction mortality by de-intensifying induction chemotherapy.
Trial ID:
Source:
Title:
Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study
Published date:
11/06/2019
Excerpt:
Patients with ND BCR/ABL1-positive ALL aged 16-64 years with PS 0-3 and sufficient organ function were included…DA was started after alloHCT only when the BCR/ABL1 signal was positive by RQ-PCR just before transplantation….Of the patients who transplanted at CR1, the 3-year EFS and OS were 74.1% (95%CI, 60.8-83.5%) and 86.1% (95%CI, 74.2-92.8%), respectively.
DOI:
https://doi.org/10.1182/blood-2019-123382
Source:
Title:
The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)
Published date:
11/06/2019
Excerpt:
...202 pts with newly diagnosed Ph+ALL who received the combination of intensive therapy (hyper-CVAD) with imatinib, dasatinib, or ponatinib were analyzed….Of the 72 pts who received HCVAD + dasatinib,...the 5-year OS rate was 30% and 59%, respectively (p=0.013).
DOI:
https://doi.org/10.1182/blood-2019-129396
Source:
Title:
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
Excerpt:
Fifty-five adult patients with Ph+ ALL were enrolled…During dasatinib treatment, 53 of 53 evaluable patients (100%) achieved a CHR (one CHRi): 49 patients (92.5%) achieved a CHR at the first BM determination at day 22, 3 at the second determination at day 43, and one at the third determination at day 57...BCR-ABL transcript levels decreased rapidly during dasatinib induction...The leukemic cell reduction was significant between days 0 and 22, days 22 and 43 (P < .0001), and days 43 and 57 (P = .0143)...Mean BCR-ABL levels appeared to be more rapidly reduced in p190+ patients, suggesting a greater susceptibility of BCR-ABLp190–expressing cells to dasatinib....dasatinib is active in patients who have developed imatinib-resistant BCR-ABL mutations, except for T315I.
DOI:
https://doi.org/10.1182/blood-2011-05-351403
Trial ID:
